Current Problems in Cancer
Volume 33, Issue 3 , Pages 194-202 , May 2009

Translation Considerations for Hyperthermic Intraperitoneal Chemotherapy

  • John H. Stewart IV, MD, FACS

      Affiliations

    • Assistant Professor of Surgery, Director of the Tumor Immunotherapy Program, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Perry Shen, MD, FACS

      Affiliations

    • Associate Professor of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Edward A. Levine, MD, FACS

      Affiliations

    • Professor of Surgery, Chief of Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

References 

  1. Meyers MA. Distribution of intra-abdominal malignant seeding: Dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med. 1973;119:198–206
  2. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22:465–472
  3. Averbach AM, Jacquet P, Sugarbaker PH. Surgical technique and colorectal cancer: Impaction on local recurrence and survival. Tumori. 1995;81(3):65–71(suppl)
  4. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery. 1987;102:71–78
  5. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–487
  6. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharmacol Sci. 1986;75:1047–1052
  7. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: Tissue concentration gradients. Am J Physiol. 1985;248(3):F425–F435
  8. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46:685–689
  9. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–572
  10. Israel VK, Jiang C, Muggia FM, Tulpule A, Jeffers S, Leichman L, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: A pharmacokinetic and toxicity study. Cancer Chemother Pharmacol. 1995;37(1-2):32–38
  11. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, et al. Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265–4269
  12. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251–1261
  13. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase ii trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group study. J Clin Oncol. 1998;16:2620–2624
  14. Stewart JH, Shen P, Russell G, Fenstermaker J, Mcwilliams L, Coldrun FM, et al. A phase Ii trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137–2145
  15. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–272
  16. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980;40:1165–1168
  17. El Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6:117–127
  18. Roti Roti JL. Cellular responses to hyperthermia (40-46°C): Cell killing and molecular events. Int J Hyperthermia. 2008;24:3–15
  19. Lepock JR. How do cells respond to their thermal environment?. Int J Hyperthermia. 2005;21:681–687
  20. Walther W, Arlt F, Fichtner I, Aumann J, Stein U, Schlag PM. Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther. 2007;6:236–243
  21. Schett G, Steiner CW, Xu Q, Smolen JS, Steiner G. TNFalpha mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated inhibition of the HSF1/hsp70 stress response. Cell Death Differ. 2003;10:1126–1136
  22. Rossi A, Ciafre S, Balsamo M, Pierimarchi P, Santoro MG. Targeting the heat shock factor 1 by RNA interference: A potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res. 2006;66:7678–7685
  23. Tu S, Mcstay GP, Boucher LM, Mak T, Beere HM, Green DR. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol. 2006;8:72–77
  24. Pagliari LJ, Kuwana T, Bonzon C, Newmeyer DD, Tu S, Beere HM, et al. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc Natl Acad Sci U S A. 2005;102:17975–17980

PII: S0147-0272(09)00030-0

doi: 10.1016/j.currproblcancer.2009.06.006

Current Problems in Cancer
Volume 33, Issue 3 , Pages 194-202 , May 2009

Article Tools

* Image Usage & Resolution